BioSpace News Archive

LEO Pharma Inc. today announced that data from across its dermatology portfolio of approved and investigational medicines will be presented at the 29th Congress of the European Academy of Dermatology and Venereology (EADV), Vienna, Oct. 29-31, 2020. EADV’s 29th Congress will be fully virtual.

Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, announced today that it will release third quarter 2020 results after the market close on Tuesday, November 10, 2020.

With nearly 70% turning to their pets to de-stress and 64% willing to have a conversation with someone they disagree with politically if that person is a pet owner, Banfield Pet Hospital® survey suggests growing power pets have in bringing people together

Datavant, the leader in helping healthcare organizations safely connect and exchange their data, and Castor, a leading provider of clinical trial technology, today announced a partnership designed to increase clinical trial efficiency and enable life sciences companies and CROs to more efficiently use real-world data.

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced it will hold a conference call on November 2, 2020 at 1:30 p.m. Pacific / 4:30 p.m. Eastern.

TVM Capital Life Science, one of the leading life sciences venture capital firms in North America and Europe, today announced the final closing of its latest fund, TVM Life Science Innovation II (TVM LSI II).

Premium Vision powers the telehealth technology which allows customers to easily renew their contact lens prescription online from the comfort of home

QIC Clinics Collaborate to Share Data and Improve Outcomes for People with Type 1 Diabetes

BioTalent Canada and the Stem Cell Network today announced the launch of BioTalent Canada’s new national bilingual online “Technical Skills Fundamentals Training Program” that will help students transition successfully to the bio-economy workforce. The announcement was made at the Stem Cell Network Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2

Virtual Incision Corporation, a medical device company pioneering a first-of-its-kind miniaturized surgical platform, today announced it has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) for the company’s MIRA® (“miniaturized in vivo robotic assistant”) Platform.